



Translational Medicine Applied to Oncology

Convegno Annuale AIFI

Milano, 31 Marzo 2014

Novuspharma Background and Story

- Founded in Q4 1998 as 'spin-out' of Boehringer Mannheim Italia with 40 FTE's
- Backed by Sofinnova, Atlas Ventures and 3i as their **first investment in Italy**;
 - About 16 Mi€ overall commitment; Invested 14,9 by Q3 2000
- IPO on Italian Nuovo Mercato on November 6, 2000 with 500 Mi€ overall valuation
- VC investors
 - Sold at IPO 450K shares and cashed 36 Mi€
 - Retained about 40% of company value



EOS Overview and Highlights


- EOS is focused on translational medicine in oncology
 - Led by serial entrepreneurs with drug development expertise;
 - Nimble internal structure with core competencies garrisoned;

- Lead program lucitanib (E-3810) has completed Phase I with safety in-line with MoA and has achieved Proof of Concept in Phase II
 - Exceptional efficacy in FGFR amplified breast cancer

- Licensed lucitanib to Servier for EU and RoW (ex US and Japan)

- EOS has been acquired by Clovis Oncology on Nov. 2013

Biotech risk/reward strategy






Lucitanib is an oral agent targeting FGFR1(2), VEGFR and CSF-1R with compelling evidence of activity in FGF-aberrant breast cancer patients, and activity in other tumors often responsive to angiogenesis inhibitors




Phase IB and IIA: Best Response



EOS Value Creation Chain

- Founded in 2006 and operative since 2007 through a seed financing by Sofinnova and Founders
- Raised € 25 Mi till 2013 from three investors:
 - Sofinnova (57%)
 - AESCAP Venture (19%)
 - Principia S.G.R. (8,3%)
- Exit November 19, 2013
 - US\$ 200 Mi upfront
 - Up to US\$ 200 Mi milestones



EOS Development Resources

Process/Stage	Internal Core Resources & Strategic Partners	Outreach
<ul style="list-style-type: none"> • Medicinal Chemistry • Scale up Synthesis 	<ul style="list-style-type: none"> ✓ Nikem 	O2H
<ul style="list-style-type: none"> • CMC • GMP Production 	<ul style="list-style-type: none"> ✓ EOS FTE CMC&QA ✓ Nerviano Medical Sciences ✓ TicinumLab  	Carbogen Amcis Solvias
<ul style="list-style-type: none"> • Pharmacology • GLP Studies • IND Package 	<ul style="list-style-type: none"> ✓ EOS Team at IRFMN ✓ Accelera  	Cerep Ambit Millipore
<ul style="list-style-type: none"> • Biomarkers Development • Human and animal ADME 	<ul style="list-style-type: none"> ✓ IFOM-IEO 	
<ul style="list-style-type: none"> • Phase I & II Clinical Studies 	<ul style="list-style-type: none"> ✓ EOS Clinical Project Manager ✓ SENDO ✓ IGR, Paris ✓ Vall d'Hebron, Barcelona ✓ IEO, Milan 	Theradex



Bioentrepreneurship: a risky business

